Digital Therapeutics for Chronic Pain Market is valued at US$ 3.0 Bn in 2024 and it is expected to reach US$ 23.58 Bn by 2034, with a CAGR of 23.0% during the forecast period of 2025-2034.
Digital therapeutics represent a transformative class of medicine for chronic pain, delivering evidence-based behavioral and psychological interventions through software. These regulated medical technologies translate proven techniques like cognitive-behavioral therapy (CBT), mindfulness, and personalized exercise into accessible digital formats. By addressing the biopsychosocial complexity of pain, they help patients reconceptualize their pain experience, develop self-management skills, and reduce medication dependence.
The field is rapidly evolving from standalone applications to integrated care pathways that combine AI-driven personalization with human coaching. This evolution is creating a new ecosystem for pain management that prioritizes functional improvement and value-based outcomes over passive symptom treatment, fundamentally reshaping how chronic pain is understood and managed across global healthcare systems.
While the growth of digital therapeutics for chronic pain is driven by the rising global prevalence of chronic conditions, a shift towards non-opioid pain management, and advancements in AI and wearable technology, the sector faces significant hurdles. Key challenges include securing consistent insurance reimbursement, demonstrating long-term efficacy to clinicians and payers, ensuring patient engagement and adherence, and navigating complex and varying regulatory frameworks across different global markets.
Some of the Key Players in the Digital Therapeutics for Chronic Pain Market:
The digital therapeutics for chronic pain market is segmented by type, delivery mode, application, and end-use. By type, the market is segmented into software-based digital therapeutics, mobile application therapeutics, and wearable device-integrated therapeutics. The delivery mode segment is segmented into self-managed and provider-guided. According to the application, the market includes neuropathic pain, musculoskeletal pain, fibromyalgia, and post-surgical pain. By end-use, the market is segmented into patients and healthcare providers.
In 2024, due to their accessibility, user-friendly interfaces, and broad smartphone adoption, mobile application therapeutics accounted for the largest segment of the digital therapeutics for chronic pain market. With these applications, users can efficiently manage their pain from the comfort of their homes, thanks to features such as pain tracking, medication reminders, guided workouts, and educational materials. Additionally, the ongoing development of app features, such as telehealth capabilities and integration with AI-driven analytics, is strengthening their value proposition and driving expansion of the digital therapeutics for chronic pain market.
In 2024, the neuropathic pain category led the digital therapeutics for chronic pain market. Because of its complexity and poor responsiveness to traditional pharmaceutical therapies, neuropathic pain—which results from nerve damage or dysfunction—is a prominent topic of focus. Additionally, advanced features such as AI-driven symptom tracking, customized fitness plans, and cognitive-behavioral therapy modules are frequently used in digital therapeutics for neuropathic pain. By helping patients better understand their pain patterns, recognize triggers, and put effective self-management techniques into practice, these solutions improve quality of life and lessen dependency on medication.
In 2024, the North America region led the digital therapeutics for chronic pain market. The region's strong rates of wearable and mobile technology use, sophisticated digital health infrastructure, and encouraging reimbursement practices are all factors contributing to its leadership. Additionally, due to significant investments in digital health innovation, a sizable population of people with chronic pain, and growing consumer and healthcare provider acceptance of digital medicines, the United States is at the forefront. With government programs advancing digital health literacy and virtual care, North America is also experiencing consistent growth.
The Asia Pacific is likely to grow at the fastest rate in the digital therapeutics for chronic pain market over the forecast period, driven by rising healthcare costs in many Asia-Pacific countries and the growing incidence of chronic pain among aging, urbanizing populations. The rapid adoption of smartphones and broadband, the growing acceptability of telehealth in the wake of the COVID-19 pandemic, and the growing use of wearables and remote monitoring devices provide the technical foundation for scalable, continuous digital medicine delivery.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 3.0 Bn |
| Revenue Forecast In 2034 | USD 23.5 Bn |
| Growth Rate CAGR | CAGR of 23.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, By Delivery Mode, By Application, By End-use, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
| Competitive Landscape | Omada Health, Kaia Health, Pear Therapeutics, Fitbit, Propeller Health, Biofourmis, Click Therapeutics, Happify Health, Akili Interactive, Better Therapeutics, Altoida, Kaiku Health, Curable, Pathway Genomics, Twill, AppliedVR, Mymee, SWORD Health, MedRhythms, MindMaze, Cognoa, Welldoc, Newtopia, Grand Rounds, and Hinge Health |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Digital Therapeutics for Chronic Pain Market by Type-
· Software-Based Digital Therapeutics
· Mobile Application Therapeutics
· Wearable Device-Integrated Therapeutics
Digital Therapeutics for Chronic Pain Market by Delivery Mode -
· Self-Managed
· Provider-Guided
Digital Therapeutics for Chronic Pain Market by Application-
· Neuropathic Pain
· Musculoskeletal Pain
· Fibromyalgia
· Post-Surgical Pain
Digital Therapeutics for Chronic Pain Market by End-use-
· Patients
· Healthcare Providers
Digital Therapeutics for Chronic Pain Market by Region-
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Digital Therapeutics for Chronic Pain Market Snapshot
Chapter 4. Global Digital Therapeutics for Chronic Pain Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Digital Therapeutics for Chronic Pain Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Digital Therapeutics for Chronic Pain Market Industry Trends
Chapter 5. Digital Therapeutics for Chronic Pain Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Software-Based Digital Therapeutics
5.2.2. Wearable Device-Integrated Therapeutics
5.2.3. Mobile Application Therapeutics
Chapter 6. Digital Therapeutics for Chronic Pain Market Segmentation 2: By Application, Estimates &
Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Application:
6.2.1. Musculoskeletal Pain
6.2.2. Neuropathic Pain
6.2.3. Fibromyalgia
6.2.4. Post-Surgical Pain
Chapter 7. Digital Therapeutics for Chronic Pain Market Segmentation 3: By Delivery Mode, Estimates & Trend Analysis
7.1. Market Share by Delivery Mode, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Mode:
7.2.1. Self-Managed
7.2.2. Provider-Guided
Chapter 8. Digital Therapeutics for Chronic Pain Market Segmentation 4: By End‑User, Estimates & Trend Analysis
8.1. Market Share by End‑User, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End‑User:
8.2.1. Patients
8.2.2. Healthcare Providers
Chapter 9. Digital Therapeutics for Chronic Pain Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Digital Therapeutics for Chronic Pain Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.2.3. North America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.2.4. North America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Mode, 2021-2034
9.2.5. North America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.3. Europe
9.3.1. Europe Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.3.3. Europe Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.3.4. Europe Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Mode, 2021-2034
9.3.5. Europe Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.4.3. Asia Pacific Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.4.4. Asia Pacific Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Mode, 2021-2034
9.4.5. Asia Pacific Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.5. Latin America
9.5.1. Latin America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.5.3. Latin America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.5.4. Latin America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Mode, 2021-2034
9.5.5. Latin America Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.6.3. Middle East & Africa Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.6.4. Middle East & Africa Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Mode, 2021-2034
9.6.5. Middle East & Africa Digital Therapeutics for Chronic Pain Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Omada Health (USA)
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Kaia Health (Germany)
10.2.3. Pear Therapeutics (USA)
10.2.4. Fitbit (USA)
10.2.5. Propeller Health (USA)
10.2.6. Biofourmis (USA)
10.2.7. Click Therapeutics (USA)
10.2.8. Happify Health (USA)
10.2.9. Akili Interactive (USA)
10.2.10. Better Therapeutics (USA)
10.2.11. Altoida (Switzerland)
10.2.12. Kaiku Health (Finland)
10.2.13. Curable (USA)
10.2.14. Pathway Genomics (USA)
10.2.15. Twill (USA)
10.2.16. AppliedVR (USA)
10.2.17. Mymee (USA)
10.2.18. SWORD Health (Portugal)
10.2.19. MedRhythms (USA)
10.2.20. MindMaze (Switzerland)
10.2.21. Cognoa (USA)
10.2.22. Welldoc (USA)